AstraZeneca plc Or Diageo plc: Which Stock Is Better For Income and Growth?

A look at two non-cyclical dividend stocks: AstraZeneca plc (LON:AZN) and Diageo plc (LON:DGE) – focussing on their recent trading conditions, near term earnings outlook and valuations.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

It may seem strange to compare Astrazeneca (LSE: AZN) with Diageo (LSE: DGE) — the two stocks do not even belong to the same sector. However, there are quite a few similarities between them — both stocks are low-beta blue-chip companies that have been seeing earnings growth falter in recent years.

Historically, both stocks have delivered a reliable combination of income and capital growth, too. Astrazeneca has delivered a total return (that is, the rate of return with dividends being reinvested in the company) of 88% over the past five years, while Diageo has managed 49%.

Remember, though, past performance is no guarantee of future results.

Should you invest £1,000 in Standard Life Investments Property Income Trust right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets. And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Standard Life Investments Property Income Trust made the list?

See the 6 stocks

Recent trading conditions

Diageo, the £47bn alcoholic beverages company, reported its interim earnings today and said that underlying EPS fell 4% to 51.3p in the six months to December 31. Although the company managed to generate a 1.8% organic growth in revenues, adverse currency movements and the disposal of non-core assets led operating profits to fall by £156m, to £1,717m.

Overall, trading conditions are challenging. The impact of adverse currency movements is largely out of the management’s control, but the company has been doing well at what it can control. It has delivered continued margin improvement and steady volumes growth. And, despite the earnings trend, free cash flow is growing, allowing Diageo to increase its interim dividend by 5% to 22.6p per share.

Astrazeneca’s earnings trend in recent years is in much worse shape. Underlying EPS has fallen by an annualised rate of 16.2% over the last three years, compared to 2.0% for Diageo, as the pharma company’s patent protection has expired on some of its “blockbuster” drugs. Ongoing launches on new treatments are just beginning to offset the trend in declining revenues, but have yet to have the same impact on earnings.

Looking forward, though, Astrazeneca’s revitalised portfolio of portfolio of investigational therapies should allow the company to emerge from its earnings slump. The pharmaceutical company has some 131 projects in our pipeline, with 15 in the late-stage of development.

We will know more about Astrazeneca’s trading performance when the company reports its full-year earnings on February 4.

Valuations

  Astrazeneca Diageo
Forward P/E 15.8 21.3
Prospective Dividend Yield 4.4% 3.0%
Adjusted Payout Ratio (2015) 64% 66%
2-year Forecast Annualised EPS Growth -6.0% 4.3%

Both companies have forward P/E ratios slightly ahead of the FTSE 100 average, but both also offer reasonably high levels of income with a dividend payout ratio of around two-thirds of underlying earnings.

Based on these valuation ratios, Astrazeneca seems to be the cheaper of the two. But, it is important to note that the company has kept its dividend frozen at $2.80 a year since 2011, and analysts expect it will remain frozen for at least another two years. With earnings forecast to decline by an annualised rate of 6.0% over the next two years, the pharmaceutical company is not exactly in a strong position to grow its dividend. Its dividend payout ratio is expected to climb from 64% in 2015, to around 74% by the end of 2017.

By contrast, Diageo’s growth prospects are more attractive. Its earnings outlook is brighter, with earnings set to grow by an annualised rate of 4.3% over the next two years. This should allow the company to maintain its a progressive dividend policy. So, whilst growth comes at a price, for me, it seems to be worth it.

But what does the head of The Motley Fool’s investing team think?

Should you invest £1,000 in Standard Life Investments Property Income Trust right now?

When investing expert Mark Rogers has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for nearly a decade has provided thousands of paying members with top stock recommendations from the UK and US markets.

And right now, Mark thinks there are 6 standout stocks that investors should consider buying. Want to see if Standard Life Investments Property Income Trust made the list?

See the 6 stocks

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Tang has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca and Diageo. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Prediction: 12 months from now, the Vodafone share price could turn £5,000 into…

Could the Vodafone share price jump by 30% over the next 12 months? Zaven Boyrazian takes a closer look at…

Read more »

happy senior couple using a laptop in their living room to look at their financial budgets
Investing Articles

Prediction: 12 months from now, the Aviva share price could turn £5,000 into…

The Aviva share price tumbled in the tariff-induced market turmoil, but could this have created a new buying opportunity for…

Read more »

Investing Articles

Prediction: 12 months from now, the BAE share price could turn £5,000 into…

With EU defence spending on the rise, the BAE Systems' share price could surge… right? Not necessarily. Zaven Boyrazian digs…

Read more »

Investing Articles

Up more than 50% in a month! What’s going on with the Greatland Gold (GGP) share price?

The Greatland Gold (GGP) share price has been the best performer on the FTSE AIM 100 index over the past…

Read more »

Investing Articles

Prediction: 12 months from now, the IAG share price could turn £5,000 into…

Zaven Boyrazian explores how high the IAG share price can fly over the next 12 months and what factors investors…

Read more »

Two white male workmen working on site at an oil rig
Investing Articles

Prediction: 12 months from now, the BP share price could turn £5,000 into…

The BP share price crashed in April following the aftermath of US tariffs and tumbling oil prices. But is this…

Read more »

Investing Articles

14.2% dividend yield! Is this FTSE income stock worth considering in 2025?

This clean energy trust offers the highest dividend yield in the FTSE 350 right now, but is the double-digit payout…

Read more »

Investing Articles

£5,000 invested in the S&P 500 at the start of 2025 is now worth…

2025 has been a bumpy ride for the S&P 500, tumbling towards a correction before falling further on tariff news…

Read more »